technology
We target disease.
SBI has spent over 30 years developing human cell-line(s) and various biotech products from its cell-differentiation technology.
SBI continues its trajectory started from President and Founder, Ramesh G. Shah, who had over 20 years of hands-on experience in research and development of products for cancer therapy and cell differentiation. While heading the research department of a Philadelphia biotech startup, he helped develop a technology for an anti-tumor product, which involved immortalization of of human (lymphoid) blood cells without using external stimulating agents. These cells can be continuously grown in culture flasks or on a larger scale in bioreactors. They are also found to secrete other useful products, besides the PB-1 anti-tumor product.
SBI acquired exclusive and irrevocable licensing rights and title to PB-1, producing cell-line and other cell-lines, as well as all products of the cell-lines from the parent company. Thus far, development of the basic technology, discovery of the product, production, purification and anti-tumor as well as toxicity studies in animal experiments have been conducted.
All earlier scientific efforts and financial resources were focussed mainly on the discovery and development of the anti-tumor product (PB-1). While carrying out this activity and also following the acquisition of PB-1, SBI has explored and identified other useful products emanating from the basic technology, through strategic alliances and collaborations.
SBI retains all proprietary rights to the products produced from this technology, and now seeks to sell the cell-line and technology for further development.
